Hidden Drugs in Sexual Enhancement Supplements Pose Severe Risks

Seven new sexual enhancement products were added to the U.S. Food and Drug Administration’s fraud database in September 2026, continuing a pattern of adulterated supplements reaching consumers through gas stations, convenience stores and e-commerce platforms.

The latest warnings involve pills, gummies, honey packets, coffee blends and chocolates marketed for sexual performance. Laboratory testing repeatedly reveals that these items contain undeclared pharmaceutical compounds, most commonly sildenafil and tadalafil, the active ingredients in prescription erectile dysfunction medications Viagra and Cialis.

Products carrying names such as Rhino, Anaconda and Magnum are sold under the regulatory umbrella of dietary supplements. Under the Dietary Supplement Health and Education Act of 1994, manufacturers bear responsibility for product safety and accurate labeling, but the FDA does not evaluate or approve supplements for safety and effectiveness before they reach store shelves. Prescription drugs, by contrast, undergo three phases of clinical trials spanning roughly a decade before approval.

That regulatory gap allows unapproved chemical analogs to circulate widely. A 2023 scientific review cataloged 112 distinct unapproved phosphodiesterase type 5 inhibitors and related compounds detected in sexual enhancement products globally between 2003 and mid-2023. Manufacturers frequently substitute modified chemical structures to evade standard laboratory screening methods designed to detect known prescription drugs.

Consuming hidden erectile dysfunction medication outside medical supervision carries immediate cardiovascular risks. Phosphodiesterase type 5 inhibitors interact dangerously with nitrate medications, including nitroglycerin prescribed for heart disease, potentially triggering fatal drops in blood pressure. The FDA began maintaining its public list of tainted health fraud products in 2007, yet officials acknowledge the database captures only a fraction of contaminated merchandise currently in circulation.

Adulteration extends beyond erectile dysfunction drugs. In May 2023, the FDA warned against Rhino 7S Type F3 7000 after tests revealed it contained both sildenafil and acetaminophen, the pain reliever sold over the counter as Tylenol. The presence of undeclared acetaminophen creates a compounding overdose risk for anyone simultaneously using cold medicines or other common painkillers. Acetaminophen toxicity remains a leading cause of acute liver failure in the United States.

International supply chains accelerate distribution faster than enforcement can respond. Ingredients may be sourced in one country, manufactured in another and shipped directly to buyers thousands of miles away. Between December 2024 and May 2025, Interpol’s Operation Pangea XVII coordinated authorities across 90 countries to seize more than 50 million doses of illicit pharmaceuticals. Erectile dysfunction medications ranked as the second-most confiscated product category worldwide, trailing only psychostimulants.

A subsequent global law enforcement operation disrupted approximately 13,000 websites, social media accounts and automated bots linked to illegal medicine sales, again identifying erectile dysfunction drugs among the highest-volume contraband.

Domestic enforcement faces structural limitations. Federal law requires certain online marketplaces to verify high-volume third-party sellers and offer consumer reporting mechanisms, but platforms face no mandate to independently test dietary supplements for hidden pharmaceuticals or proactively flag adulterated listings to regulators.

Labeling rules compound consumer confusion. Terms like “natural” or “herbal” imply botanical ingredients, yet U.S. regulations do not require supplement labels to warn buyers that such products might secretly contain synthetic drugs. The FDA mandates specific disclaimers when supplements make functional claims, but those disclosures address general regulatory status rather than contamination risks.

Researchers tracking a European sexual enhancement supplement branded as “POWER” from 2007 through 2022 found phosphodiesterase type 5 inhibitors in every tested version, though the exact chemical adulterants shifted over time to bypass detection. Despite repeated seizures and public warnings from European health authorities, the product remained available for purchase online at the conclusion of the study.

Independent testing conducted on 158 sexual enhancement supplements sold in the United Arab Emirates found undeclared sildenafil, tadalafil or vardenafil in more than 12% of the samples, confirming that contamination spans multiple continents and retail environments.

The FDA has not issued additional public alerts regarding the seven products flagged in September 2026 beyond their inclusion in the agency’s existing Tainted Products Marketed as Dietary Supplements database.